EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers

Sara Manore, Chuling Zhuang iD, Mariana K Najjar iD, Grace L Wong iD, Shivani Bindal, Kounosuke Watabe, Jiayuh Lin iD, Hui-Wen Lo iD

Cells · 2024

DOI: 10.3390/cells13242087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Sara Manore und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Cytokine Receptor gp130, Triple Negative Breast Neoplasms, Ketoconazole, Indoles. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defense, NCI NIH HHS, MetaVivor.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer stem cells (CSCs) are resistant to most cancer therapeutics and contribute to tumor recurrence and metastasis. Two breast CSC-promoting transcription factors, truncated glioma-associated oncogene homolog 1 (tGLI1) and signal transducer and activator of transcription 3 (STAT3), have been reported to be frequently co-expressed in HER2-enriched breast cancer and triple-negative breast cancer (TNBC), undergo protein-protein interactions for gene regulation and activation, and functionally cooperate to promote breast CSCs. STAT3 can be activated by activated interleukin-6 receptor/glycoprotein-130 (IL-6R/GP130). Co-targeting of tGLI1 and IL-6R/GP130 has not been investigated in breast cancer or any tumor type. Here, we report that tGLI1 and GP130 are co-overexpressed in the majority of HER2-enriched breast cancers and TNBCs at 53.8% and 44.4%, respectively. tGLI1+IL-6/IL-6R/GP130 signaling is frequently co-enriched and co-activated in HER2-enriched breast cancer and TNBC when compared to luminal subtypes. tGLI1+GP130 co-overexpression strongly promotes CSCs of HER2-enriched breast cancer and TNBC. FDA-approved tGLI1 inhibitor Ketoconazole and GP130 inhibitor Bazedoxifene synergize against breast cancer proliferation and CSC phenotypes in vitro and reduce TNBC tumor growth and metastatic burden in vivo. Our study demonstrates, for the first time, that co-targeting tGLI1 and IL-6R/GP130/STAT3 signaling pathways is synergistic against HER2-enriched breast cancer and TNBC, warranting future clinical investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytokine Receptor gp130Triple Negative Breast NeoplasmsKetoconazoleIndolesCell ProliferationHumansFemaleAnimalsCell Line, TumorMiceNeoplasm MetastasisDrug SynergismErb-b2 Receptor Tyrosine KinasesSTAT3 Transcription FactorXenograft Model Antitumor AssaysSignal Transduction

Stichwörter der Autor:innen

GP130HER2-enriched breast cancerIL-6STAT3TNBCbazedoxifenebreast CSCscombination therapyketoconazoletGLI1

Substanzen

Cytokine Receptor gp130KetoconazoleIndolesErb-b2 Receptor Tyrosine KinasesSTAT3 Transcription Factorbazedoxifene

Autor:innen und Institutionen

  • Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  • Wake Forest Graduate School of Biomedical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
  • Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  • Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
  • Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

ORCID-Profile: Chuling Zhuang, Mariana K Najjar, Grace L Wong, Jiayuh Lin, Hui-Wen Lo

Förderung

  • Department of Defense
  • NCI NIH HHS
  • MetaVivor
  • NIH HHS
  • DoD
  • NIH

Zitieren

APA

Manore, S., Zhuang, C., Najjar, M. K., Wong, G. L., Bindal, S., Watabe, K., Lin, J., & Lo, H. W. (2024). Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells. https://doi.org/10.3390/cells13242087

Vancouver

Manore S, Zhuang C, Najjar MK, Wong GL, Bindal S, Watabe K, et al. Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells. 2024. doi:10.3390/cells13242087

BibTeX
@article{Manore2024,
  author = {Manore, Sara and Zhuang, Chuling and Najjar, Mariana K and Wong, Grace L and Bindal, Shivani and Watabe, Kounosuke and Lin, Jiayuh and Lo, Hui-Wen},
  title = {Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13242087}
}
Kostenlos starten →